๐๐ฟ๐ฒ๐ฎ๐ธ๐๐ต๐ฟ๐ผ๐๐ด๐ต ๐ถ๐ป ๐ฏ๐ ๐ฃ๐ฟ๐ถ๐ป๐๐ถ๐ป๐ด ๐ก๐ฎ๐ป๐ผ๐๐ฒ๐ฐ๐ต ๐๐บ๐ฝ๐ฟ๐ผ๐๐ฒ๐ ๐๐ฒ๐น๐ถ๐๐ฒ๐ฟ๐ ๐ผ๐ณ ๐๐๐ฑ๐ฟ๐ผ๐ฝ๐ต๐ผ๐ฏ๐ถ๐ฐ ๐๐ฟ๐๐ด๐ ๐น๐ถ๐ธ๐ฒ ๐๐ฏ๐๐ฝ๐ฟ๐ผ๐ณ๐ฒ๐ป Our ibuprofen research chemical was utilised in a study recently published in the European Journal of Pharmaceutics and Biopharmaceutics. Researchers from Uppsala University in Sweden used 3D printing to incorporate drug-loaded magnesium carbonate nanomaterials into formulations. This approach improves drug loading and solubility for poorly soluble medications like ibuprofen. Explore our ibuprofen research chemicals: https://okt.to/fw6d1O Read the study: https://okt.to/ybdgiP #ProductCitation #ResearchChemicals #pharma #DrugDelivery
Toronto Research Chemicals
Chemical Manufacturing
Toronto, Ontario 19,686 followers
Products for innovative research | Science for a Safer World
About us
Toronto Research Chemicals, TRC, was founded in 1982 by Dr. David Dime to manufacture and supply researchers in the biomedical fields with specialized complex organic small molecules that were not commercially available. In 1983, the company was incorporated in Ontario as Toronto Research Chemicals Inc. It was initially located at the University of Toronto. As the business expanded, larger facilities were required to accommodate the growth. Today, Toronto Research Chemicals Inc. employs over 450 full-time staff, of which approximately 250 are PhD's and MSc's, operating in 120,000 square feet of facilities. TRC has over 350,000 products offered in our extensive catalogue. Our inventory exceeds 38,000 different compounds for immediate shipment to more than 120 countries. Why Choose Toronto Research Chemicals? - We specialize in providing high-quality bio-chemicals in custom pack sizes to satisfy any quantity required. - We distribute to companies worldwide, usually, providing overnight delivery in North America via Federal Express. - We also offer alternative carrier options to meet worldwide delivery and special import requirements. - We have a dedicated and professional customer service team positioned to ensure customer satisfaction and technical support. *In August of 2019, TRC became a subsidiary of LGC. LGC acquired Toronto Research Chemicals, strengthening our overall presence in the global reference standards market.
- Website
-
http://www.lgcstandards.com/TRC
External link for Toronto Research Chemicals
- Industry
- Chemical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Toronto, Ontario
- Type
- Privately Held
- Founded
- 1982
- Specialties
- Chemistry, Analytical Services, Custom Synthesis, Chemical Manufacturing, and Customer Service
Locations
-
Primary
20 Martin Ross Ave
Toronto, Ontario M3J 2K8, CA
Employees at Toronto Research Chemicals
Updates
-
๐๐ข๐ฌ๐๐จ๐ฏ๐๐ซ ๐ญ๐ก๐ ๐ค๐๐ฒ ๐ญ๐จ ๐๐ง๐ฌ๐ฎ๐ซ๐ข๐ง๐ ๐๐ซ๐ฎ๐ ๐ฌ๐ญ๐๐๐ข๐ฅ๐ข๐ญ๐ฒ ๐๐ง๐ ๐ซ๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐๐จ๐ฆ๐ฉ๐ฅ๐ข๐๐ง๐๐ ๐ฐ๐ข๐ญ๐ก ๐จ๐ฎ๐ซ ๐ง๐๐ฐ ๐ฐ๐ก๐ข๐ญ๐ ๐ฉ๐๐ฉ๐๐ซ ๐จ๐ง ๐๐จ๐ซ๐๐๐ ๐๐๐ ๐ซ๐๐๐๐ญ๐ข๐จ๐ง ๐ฌ๐ญ๐ฎ๐๐ข๐๐ฌ! This essential guide integrates industry insights, scientific literature, and regulatory guidelines to help you design effective stress testing protocols. Learn how to identify real-world degradation pathways, create robust stability-indicating methods, and enhance drug approval and formulation processes. Enhance your pharmaceutical testing and development with our white paper: https://okt.to/nHMXrm #Pharmaceutical #stresstesting #ImpurityStandards #impurities #APIs #ReferenceStandards
-
The World Health Organisation has released draft guidelines to combat the presence of potentially carcinogenic nitrosamine impurities in medicines. These guidelines, building on the efforts of the FDA and EMA, offer detailed advice on Good Manufacturing Practices, risk assessment, root cause analysis, and analytical procedures. This critical update aims to enhance the safety of drug products by ensuring rigorous identification and control of nitrosamine impurities, thereby maintaining the global supply of essential medicines. Read the article to learn more: https://okt.to/nWCKxV #pharma #Nitrosamines #WHOGuidelines #drugmanufacturing
WHO releases new guidelines for preventing nitrosamine contamination
lgcstandards.com
-
๐ก๐ฎ๐ป๐ผ๐ฝ๐ฎ๐ฟ๐๐ถ๐ฐ๐น๐ฒ-๐๐ฒ๐น๐ถ๐๐ฒ๐ฟ๐ฒ๐ฑ, ๐จ๐ฉ-๐๐ฐ๐๐ถ๐๐ฎ๐๐ฒ๐ฑ ๐๐ต๐ฒ๐บ๐ผ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ ๐๐ณ๐ณ๐ฒ๐ฐ๐๐ถ๐๐ฒ ๐ถ๐ป ๐๐ฟ๐ฒ๐ฎ๐๐ ๐๐ฎ๐ป๐ฐ๐ฒ๐ฟ ๐ ๐ผ๐ฑ๐ฒ๐น๐ Breast cancer, a disease affecting millions worldwide, often requires chemotherapy, which can cause serious side effects due to off-target toxicity. Improved, targeted drug delivery technologies aim to enhance efficacy and reduce toxicity by precisely targeting tumours, thereby improving outcomes and minimizing side effects. We're excited to share a study using our TRC research chemicals to develop a gold nanoparticle system for delivering the chemotherapy drug doxycycline, which can be activated at the tumour site using UV light. Recently published by Turkish scientists at Hacettepe University, these preclinical studies show promising progress. Read on at https://okt.to/GLo102. ๐ก TRC supports you from target identification to drug development and toxicology, view our extensive range at https://okt.to/08Kbw4 #ProductCitation #ResearchChemicals #CancerReseacrch
-
Nanotechnology is revolutionising drug delivery by tackling the key challenges in solubility and bioavailability that significantly impact drug efficacy. Some of the most promising nano drug delivery systems currently being studied are metal-organic frameworks (MOFs), carbon nanotubes (CNTs), mesoporous silica nanoparticles (MSNs), nanoemulsions, and solid lipid nanoparticles. Read our latest blog post to explore the key issues and trends in nano drug delivery techniques at https://okt.to/EqIG3M #nanotechnology #nanoparticles #DrugDelivery #pharma #SILS
Nanotechnology in Drug Delivery | LGC Standards
lgcstandards.com
-
๐ก๐ฎ๐ป๐ผ๐ฝ๐ฎ๐ฟ๐๐ถ๐ฐ๐น๐ฒ๐ ๐ฆ๐๐ฐ๐ฐ๐ฒ๐๐๐ณ๐๐น๐น๐ ๐๐ฒ๐น๐ถ๐๐ฒ๐ฟ ๐๐ป๐๐ถ๐ฟ๐ฒ๐๐ฟ๐ผ๐๐ถ๐ฟ๐ฎ๐น (๐๐ฅ๐ง) ๐๐ฟ๐๐ด๐ ๐๐ผ ๐๐ต๐ฒ ๐๐ฟ๐ฎ๐ถ๐ป The progress in HIV/AIDS treatment, with many patients achieving undetectable virus levels through effective antiretroviral therapy (ART) regimens, showcases the success of modern drug discovery. However, HIV can invade the brain as early as eight days post-infection, residing in white blood cells. The limited ability of ART to cross the blood-brain barrier presents a significant challenge, leading to numerous HIV-associated brain disorders. Improvements in drug formulation and targeting are needed to meet these clinical needs. Weโre delighted to learn about the use of our darunavir research chemical in a study that developed polymer-coated nanoparticles to deliver ART drugs into mice brains. Published recently in Pharmaceutics, these findings offer hope for a clinical breakthrough for HIV-related CNS infections. Learn more about the research chemical and related product citations at https://okt.to/qiYUAP #ProductCitation #antiretroviral #nanoparticles #ResearchChemicals
Darunavir Nanoformulation Suppresses HIV Pathogenesis in Macrophages and Improves Drug Delivery to the Brain in Mice
mdpi.com
-
Discover the power of precision medicine in cancer treatment with this insightful infographic! Gain a deeper understanding of how personalized therapies can make a difference in the lives of cancer patients. This infographic highlights the importance of targeting mutations in cancer and how it can revolutionize patient care. Download the infographic at https://okt.to/wv9S6L #PrecisionMedicine #CancerTreatment #TargetedTherapies #Infographic
Targeting Mutations in Cancer: Past Present and Future
-
Targeting all KRAS oncogenic variants: a viable path to tangible therapeutic impact? KRAS was at one time considered undruggable. However, persistent efforts led to the approval of two KRAS mutant inhibitors. Here we review further KRAS inhibition strategies and consider their enormous therapeutic potential. Read our white paper today: https://okt.to/xo5Ggv #KRAS #Oncology #OncologyResearch #CancerResearch #Inhibitors
TRC White paper | Download your free copy now!
documents.lgcstandards.com
-
Recently, researchers have explored the potential benefits of ayahuasca. This Amazonian plant medicine contains the psychedelic compound DMT and harmine alkaloids and is believed to offer therapeutic effects for patients with affective and mental health disorders. However, the way ayahuasca is processed in the body causes problems for clinical use. We are thrilled to share that our TRC research chemicals were used to support a study in which researchers have developed an enhanced formulation currently in clinical trials. Read the findings in the journal Frontiers in Pharmacology: https://okt.to/C0o24j #ProductCitation #pharmacology #neuroscience #ResearchChemicals
Frontiers | Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine